Janssen Enriches Crohn&39;s Portfolio In Deal For Protagonist&39;s Oral IL23 Inhibitor

J&J&39;s Janssen committed up to $990m plus royalties to collaborate with peptide drug developer Protagonist on an oral IL23 inhibitor...&160;&160;&160;